All News

According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.

The addition of short-term androgen deprivation to dose-escalated radiation therapy did not yield a significant difference in quality-of-life outcomes vs radiotherapy alone for those with intermediate-risk prostate cancer, according to an expert from Henry Ford Health Cancer.

The novel radiotherapy Iomab-B prolongs survival and improves clinical outcomes among patients with relapsed/refractory acute myeloid leukemia, according to data from the phase 3 SIERRA trial.

James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.

“Even in well-resourced countries, there are disparities in exposure to treatments; some of these are rooted deeply in social determinants of health and represent a very complex problem of providing equal access.”

Data from the phase 2 TITAN-TCC trial suggest that early non-responders with metastatic urothelial carcinoma with PD-L1–positive tumors benefit from nivolumab plus nivolumab/ipilimumab boosts.

In the phase 3 RENOTORCH trial, frontline toripalimab plus axitinib appears to improve the overall response rate of patients with unresectable or metastatic renal cell carcinoma.

An update to the ASTRO and ESTRO clinical guidelines highlights the importance of a multidisciplinary approach to treating oligometastatic non–small cell lung cancer.

The impact of the gut microbiome, and antibiotics and probiotics on immunotherapy outcomes are areas of research currently under investigation for patients with kidney cancer and other cancers, according to an expert from University Hospitals.

Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.

Findings from the phase 3 OUTBACK trial show that following standard cisplatin-based chemotherapy with adjuvant chemotherapy resulted in increased toxicity among patients with cervical cancer.

The 31-gene expression profile test appears to allow for significant and independent risk stratification of those with stage I cutaneous melanoma.

Results from a phase 2 study support additional clinical trials assessing belzutifan-based regimens for patients with advanced clear cell renal cell carcinoma.

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.

Patients with curable metastatic cancer appear to have long-lasting improvements in depression symptoms 8 weeks after a single treatment with psilocybin therapy.

The safety profile of adagrasib monotherapy in advanced solid tumors harboring KRAS G12C mutations appears manageable, according to an expert from The University of Texas MD Anderson Cancer Center.

Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.

Toripalimab plus chemotherapy appears tolerable in patients with resectable stage III non–small cell lung cancer, according to an expert from Shanghai Lung Cancer Center.

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the effects and prevalence of burnout amongst oncologists and reviews strategies to address the issue.

The European Medicines Agency validates the potential indication of dostarlimab/chemotherapy in mismatch repair deficient/microsatellite instability–high endometrial cancer based on the phase 3 RUBY trial.

Investigators report that patients with advanced or metastatic esophageal squamous cell carcinoma may have superior overall survival benefit following treatment with tislelizumab/chemotherapy vs placebo/chemotherapy.

The phase 3 SPLASH trial will assess the benefit of 177Lu-PNT2002 in patients with PSMA-expressing metastatic castration-resistant prostate cancer.

Investigators cite the need for further study of the 25 mg, 3 times weekly exemestane dosing schedule in prevention studies among those with post-menopausal, stage 0 to II estrogen receptor–positive breast cancer who can’t tolerate daily adjuvant treatment.

Data from the phase 3 MAGNITUDE study support the European Commission’s approval of niraparib plus abiraterone acetate dual action tablets in BRCA-mutated metastatic castration-resistant prostate cancer.

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Adding fulvestrant to alisertib does not appear to improve objective in patients with endocrine-resistant metastatic breast cancer in the phase 2 TBCRC041 trial.

Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.

The FDA extends the Prescription Drug User Fee Act date to July 24, 2023 for quizartinib in the management of newly diagnosed FLT3-ITD mutation–positive acute myeloid leukemia.

An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.